Avacopan与糖皮质激素治疗重症ANCA相关急进性肾小球肾炎的比较
该研究纳入70例重症ANCA-RPGN且肾活检可用的成人患者,比较以Avacopan或糖皮质激素为基础的诱导方案在第6和12个月的肾脏结局。经组织病理学调整后,两种诱导方案在肾脏缓解方面相似,Avacopan组未发现新安全信号,但3例因可逆性肝炎需停用Avacopan。
要点
- 重症ANCA-RPGN患者中,Avacopan联合短程激素与激素方案的肾脏恢复率相似。
- 经组织病理学调整后,诱导方案(RTX、CYC或两者)及Avacopan或激素方案与第6个月肾脏缓解相似相关。
- Avacopan组3例出现需停药的可逆性肝炎,未发现其他新安全信号。
核心结论
- 在第6和12个月,接受Avacopan联合短程糖皮质激素的重症ANCA-RPGN患者与接受糖皮质激素方案的患者肾脏恢复率相似。
研究设计与样本
- 队列研究纳入70例成人重症ANCA-RPGN患者,eGFR为0-30 ml/min per 1.73 m2(均值12±8),抗MPO抗体阳性76%,复发性AAV占6%,且均有肾活检可用。
主要发现
- 每组半数患者接受血浆置换。
- 新月体肾小球百分比与就诊时eGFR相关,肾小球硬化百分比与第6个月最大肾脏改善相关。
- 经组织病理学调整后,诱导方案(RTX、CYC或两者)以及使用糖皮质激素或Avacopan为基础的诱导方案与第6个月肾脏缓解相似相关,无论采用何种终点。
- Avacopan组3例出现需停药的可逆性肝炎,未发现新安全信号。
临床怎么用
- 对于重症ANCA-RPGN且eGFR极低的患者,Avacopan联合短程糖皮质激素可作为糖皮质激素方案的替代选择,肾脏恢复率相似。
- 使用Avacopan期间需监测肝炎相关指标,出现可逆性肝炎时应考虑停药。
局限性
- 研究为队列设计,样本量70例,Avacopan组仅20例,可能存在选择偏倚和混杂。
- 原文未报告 statistical power 或置信区间等详细信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The best immunosuppressive regimen to treat severe forms of antineutrophil cytoplasmic autoantibody (ANCA)-associated rapidly progressive glomerulonephritis (RPGN) remains elusive because patients with the lowest estimated glomerular filtration rate (eGFR) have been excluded from most studies, and kidney biopsy has not been a prerequisite for inclusion. METHODS: In a cohort of 70 adult patients with severe ANCA-RPGN (eGFR: 0-30 ml/min per 1.73 m2 [mean: 12 ± 8]; anti-myeloperoxidase [MPO] antibodies: 76%, relapsing ANCA-associated vasculitis [AAV]: 6%) where a kidney biopsy was available, we compared kidney outcomes at month 6 and 12 according to induction regimen scheme (avacopan- vs. glucocorticoid [GC]-based). RESULTS: Fifty patients received a GC regimen combined with cyclophosphamide (CYC) (30%), rituximab (RTX, 54%) or a combination of both (16%), whereas 20 patients received avacopan combined with RTX (90%) or RTX plus CYC (10%). Half of the patients in each group received plasma exchanges. The percentage of crescentic glomeruli (a reliable marker of kidney vasculitis activity) correlated with eGFR at presentation, whereas the percentage of glomerulosclerosis (a surrogate marker for chronic kidney lesions) correlated with maximal kidney improvement at month 6. After adjustment for histopathology, the induction regimen (RTX, CYC, or both) as well as the use of GCs or avacopan-based induction regimen were associated with similar kidney response at month 6, whatever end point was used. Reversible hepatitis requiring avacopan withdrawal occurred in 3 patients. No new safety signal was identified in the avacopan group. CONCLUSION: At months 6 and 12, patients with severe forms of ANCA-RPGN and receiving avacopan plus a short course of GCs have similar kidney recovery rates to patients receiving GC regimen.
引用
- Faguer S, Gabilan C, Colombat M, et al. Avacopan or Glucocorticoids for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Rapidly Progressive Glomerulonephritis. Kidney Int Rep. 2025. PMID: 41278345. doi:10.1016/j.ekir.2025.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。